A Phase 3 Study of LY2189265 Monotherapy Compared to Placebo and Liraglutide in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dulaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2015 Results published in an Eli Lilly Media Release.
- 06 Jun 2015 Primary endpoint has been met. (Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks) as per an Eli Lilly media release.